168 related articles for article (PubMed ID: 2185354)
1. Diabetic nephropathy in normotensive patients.
Mimran A; Ribstein J
J Hypertens Suppl; 1990 Mar; 8(1):S53-9; discussion S59-60. PubMed ID: 2185354
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure reduction as a preventive treatment of diabetic nephropathy.
Ribstein J; Mimran A
Clin Invest Med; 1991 Dec; 14(6):661-70. PubMed ID: 1794216
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
Baba T; Ishizaki T
Drugs; 1992 Apr; 43(4):464-89. PubMed ID: 1377114
[TBL] [Abstract][Full Text] [Related]
4. Renal protection and antihypertensive drugs: current status.
Salvetti A; Mattei P; Sudano I
Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
[TBL] [Abstract][Full Text] [Related]
5. Is antihypertensive treatment the same for NIDDM and IDDM patients?
Parving HH
Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S43-7. PubMed ID: 9649959
[TBL] [Abstract][Full Text] [Related]
6. Renal protection in diabetes: an emerging role for calcium antagonists.
Parving HH; Tarnow L; Rossing P
J Hypertens Suppl; 1996 Nov; 14(4):S21-5. PubMed ID: 8986939
[TBL] [Abstract][Full Text] [Related]
7. Effects of antihypertensive therapy on progression of diabetic nephropathy.
Luño J; Garcia de Vinuesa S; Gomez-Campdera F; Lorenzo I; Valderrábano F
Kidney Int Suppl; 1998 Dec; 68():S112-9. PubMed ID: 9839294
[TBL] [Abstract][Full Text] [Related]
8. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
Parving HH; Rossing P
Curr Opin Nephrol Hypertens; 1994 May; 3(3):292-300. PubMed ID: 7922255
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.
Parving HH
J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S19-24. PubMed ID: 1382160
[TBL] [Abstract][Full Text] [Related]
10. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
Hommel E
J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
[TBL] [Abstract][Full Text] [Related]
11. Renal protection in diabetes--an emerging role for calcium antagonists.
Parving HH; Tarnow L; Rossing P
Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
[TBL] [Abstract][Full Text] [Related]
12. Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
Parving HH
J Hypertens Suppl; 1998 Jan; 16(1):S99-101. PubMed ID: 9534107
[TBL] [Abstract][Full Text] [Related]
13. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Sato A; Tabata M; Hayashi K; Saruta T
Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
[TBL] [Abstract][Full Text] [Related]
14. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
15. The management of diabetic proteinuria. Which antihypertensive agent?
Cooper ME; Doyle AE
Drugs Aging; 1992; 2(4):301-9. PubMed ID: 1504444
[TBL] [Abstract][Full Text] [Related]
16. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus.
Parving HH
Diabetes Care; 1991 Mar; 14(3):260-9. PubMed ID: 2044441
[TBL] [Abstract][Full Text] [Related]
17. Diabetic nephropathy: from micro- to macroalbuminuria.
Deferrari G; Repetto M; Calvi C; Ciabattoni M; Rossi C; Robaudo C
Nephrol Dial Transplant; 1998; 13 Suppl 8():11-5. PubMed ID: 9870419
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
Thomas MC; Atkins RC
Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
[TBL] [Abstract][Full Text] [Related]
19. Evolving strategies for renoprotection: diabetic nephropathy.
Parving HH; Hovind P; Rossing K; Andersen S
Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):515-22. PubMed ID: 11458033
[TBL] [Abstract][Full Text] [Related]
20. Preventing end-stage renal disease.
Mogensen CE
Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
